NASDAQ:QLGN

Qualigen Therapeutics Stock Forecast, Price & News

$2.13

-0.47 (-18.08 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.10

Now: $2.13▼

$2.35

50-Day Range

$2.60

MA: $3.03▼

$3.97

52-Week Range

$2.10

Now: $2.13▼

$19.75

Volume2.53 million shs

Average Volume1.53 million shs

Market Capitalization$49.12 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.72

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QLGN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.qualigeninc.com

Phone760-918-9165

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio0.76

Quick Ratio0.73

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.13) per share

Price / Book-1.88

Profitability

EPS (Most Recent Fiscal Year)($26.50)

Net Income$-1,670,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-91.03%

Miscellaneous

Outstanding Shares23,061,000

Market Cap$49.12 million

Next Earnings Date5/7/2021 (Estimated)

OptionableNot Optionable

Headlines

Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Invest In Growth?
April 6, 2021 | finance.yahoo.com

Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
March 18, 2021 | finance.yahoo.com

Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
March 9, 2021 | finance.yahoo.com

Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
March 8, 2021 | finance.yahoo.com

Qualigen Therapeutics, Inc.: Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 1, 2021 | finanznachrichten.de

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 1, 2021 | finance.yahoo.com

Best Penny Stocks To Buy Before Friday? 4 Under $4 To Watch
February 25, 2021 | marketwatch.com

Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
January 5, 2021 | benzinga.com

Insider Buys Qualigen Therapeutics Stock
December 30, 2020 | benzinga.com

Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook
December 22, 2020 | finance.yahoo.com

Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
December 18, 2020 | finance.yahoo.com

Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering
December 16, 2020 | finance.yahoo.com

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology
December 15, 2020 | finance.yahoo.com

Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board
December 8, 2020 | finance.yahoo.com

Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials
December 2, 2020 | finance.yahoo.com

QLGN: Testing AS1411 as COVID-19 Treatment…
November 30, 2020 | finance.yahoo.com

Qualigen Therapeutics EPS misses by $0.61, misses on revenue
November 14, 2020 | seekingalpha.com

Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
November 13, 2020 | finance.yahoo.com

Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials
November 5, 2020 | finance.yahoo.com

Qualigen Therapeutics, Inc. Common Stock (QLGN)
November 3, 2020 | nasdaq.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.13 out of 5 stars

Medical Sector

972nd out of 2,016 stocks

Pharmaceutical Preparations Industry

457th out of 771 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Qualigen Therapeutics.

5.0 Community Rank

Outperform Votes
Qualigen Therapeutics has received 5 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Qualigen Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Qualigen Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Qualigen Therapeutics and other stocks. Vote “Outperform” if you believe QLGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QLGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Qualigen Therapeutics does not currently pay a dividend.
Dividend Growth
Qualigen Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.40% of the stock of Qualigen Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.50% of the stock of Qualigen Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Qualigen Therapeutics are expected to grow in the coming year, from ($1.74) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Qualigen Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Qualigen Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$2.13

-0.47 (-18.08 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive QLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Qualigen Therapeutics (NASDAQ:QLGN) Frequently Asked Questions

Is Qualigen Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Qualigen Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Qualigen Therapeutics stock.
View analyst ratings for Qualigen Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Qualigen Therapeutics?

Wall Street analysts have given Qualigen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Qualigen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Qualigen Therapeutics' next earnings date?

Qualigen Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for Qualigen Therapeutics.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) issued its quarterly earnings data on Thursday, November, 19th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.31. The business had revenue of $0.84 million for the quarter, compared to analysts' expectations of $1.40 million.
View Qualigen Therapeutics' earnings history.

Who are Qualigen Therapeutics' key executives?

Qualigen Therapeutics' management team includes the following people:

Mr. Michael S. Poirier, Chairman, CEO & Pres (Age 65)
Mr. Christopher L. Lotz, VP of Fin. & CFO (Age 56)
Mr. Shishir K. Sinha, VP of Operations & Corp. Sec. (Age 53)
Dr. Wajdi Abdul-Ahad, VP of R&D and Chief Scientific Officer (Age 68)
Ms. Amy S. Broidrick, Exec. VP, Chief Strategy Officer & Director

Who are some of Qualigen Therapeutics' key competitors?

Some companies that are related to Qualigen Therapeutics include Galera Therapeutics (GRTX), Osmotica Pharmaceuticals (OSMT), Aptinyx (APTX), Equillium (EQ), IMV (IMV), CTI BioPharma (CTIC), OptiNose (OPTN), Genprex (GNPX), Eton Pharmaceuticals (ETON), Enlivex Therapeutics (ENLV), Lantern Pharma (LTRN), Harrow Health (HROW), Heat Biologics (HTBX), DiaMedica Therapeutics (DMAC) and scPharmaceuticals (SCPH).
View all of QLGN's competitors.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), The Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Blockchain (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "QLGN."

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qualigen Therapeutics' stock price today?

One share of QLGN stock can currently be purchased for approximately $2.13.

How much money does Qualigen Therapeutics make?

Qualigen Therapeutics has a market capitalization of $49.12 million. The company earns $-1,670,000.00 in net income (profit) each year or ($26.50) on an earnings per share basis.

What is Qualigen Therapeutics' official website?

The official website for Qualigen Therapeutics is www.qualigeninc.com.

Where are Qualigen Therapeutics' headquarters?

Qualigen Therapeutics is headquartered at 2042 Corte Del Nogal, Carlsbad CA, 92011.

How can I contact Qualigen Therapeutics?

Qualigen Therapeutics' mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The company can be reached via phone at 760-918-9165 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here